Antibody biodistribution coefficients

Tissue vs. plasma concentration profiles have been generated from a physiologically-based pharmacokinetic model of monoclonal antibody (mAb). Based on the profiles, we hypothesized that a linear relationship between the plasma and tissue concentrations of non-binding mAbs could exist; and that the relationship may be generally constant irrespective of the absolute mAb concentration, time, and animal species being analyzed. The hypothesis was verified for various tissues in mice, rat, monkey, and human using mAb or antibody-drug conjugate tissue distribution data collected from diverse literature. The relationship between the plasma and various tissue concentrations was mathematically characterized using the antibody biodistribution coefficient (ABC). Estimated ABC values suggest that typically the concentration of mAb in lung is 14.9%, heart 10.2%, kidney 13.7%, muscle 3.97%, skin 15.7%, small intestine 5.22%, large intestine 5.03%, spleen 12.8%, liver 12.1%, bone 7.27%, stomach 4.98%, lymph node 8.46%, adipose 4.78%, brain 0.351%, pancreas 6.4%, testes 5.88%, thyroid 67.5% and thymus is 6.62% of the plasma concentration. The validity of using the ABC to predict mAb concentrations in different tissues of mouse, rat, monkey, and human species was evaluated by generating validation data sets, which demonstrated that predicted concentrations were within 2-fold of the observed concentrations. The use of ABC to infer tissue concentrations of mAbs and related molecules provides a valuable tool for investigating preclinical or clinical disposition of these molecules. It can also help eliminate or optimize biodistribution studies, and interpret efficacy or toxicity of the drug in a particular tissue.

[1]  J. Balthasar,et al.  Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts , 2012, The AAPS Journal.

[2]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Christilyn P. Graff,et al.  Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  W. Oyen,et al.  Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 , 2011, Clinical Cancer Research.

[5]  F. Theil,et al.  Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. , 2011, Bioconjugate chemistry.

[6]  W. Oyen,et al.  Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody , 2011, The Journal of Nuclear Medicine.

[7]  Y. Vugmeyster,et al.  Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice , 2010, mAbs.

[8]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[9]  Y. Vugmeyster,et al.  Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. , 2010, Journal of pharmaceutical sciences.

[10]  A. Scott,et al.  Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers , 2009, Clinical Cancer Research.

[11]  D. Benjamin,et al.  The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  Joseph P. Balthasar,et al.  Investigation of the Influence of FcRn on the Distribution of IgG to the Brain , 2009, The AAPS Journal.

[13]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[14]  Y. Vugmeyster,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. , 2008, International immunopharmacology.

[15]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  R. Senekowitsch,et al.  Pharmacokinetics of reshaped MAb 425 in three animal species , 1995, Cell Biophysics.

[17]  A. Garg Investigation of the role of FcRn in the absorption, distribution, and elimination of monoclonal antibodies , 2007 .

[18]  C. R. Leemans,et al.  (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  B. Cornelissen,et al.  In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model , 2005, Clinical Cancer Research.

[20]  José de Souza Filho,et al.  Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131 , 2005 .

[21]  Anna M. Wu,et al.  A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[22]  R. Hansen,et al.  Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.

[23]  D. Bigner,et al.  Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. , 2004, Nuclear medicine and biology.

[24]  W. Oyen,et al.  Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. , 2004, Cancer biotherapy & radiopharmaceuticals.

[25]  Hongsheng Xie,et al.  Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  Ryosei Kawai,et al.  Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  L. Khawli,et al.  Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. , 2002, Cancer biotherapy & radiopharmaceuticals.

[28]  V. Muzykantov,et al.  Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[29]  W. Pardridge,et al.  Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier , 2001, Journal of Neuroimmunology.

[30]  L. Zuckier,et al.  Expression of human tumor mucin-associated carbohydrate epitopes, including sialylated Tn, and localization of murine monoclonal antibodies CC49 and B72.3 in a syngeneic rat colon carcinoma model. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[31]  R K Jain,et al.  Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.

[32]  J. Baak,et al.  Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. , 1993, Cancer research.

[33]  F. Buchegger,et al.  Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  V. Muzykantov,et al.  Endotoxin reduces specific pulmonary uptake of radiolabeled monoclonal antibody to angiotensin-converting enzyme. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Eary,et al.  Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. , 1991, Blood.